Finerenone is a novel non-steroidal mineralocorticoid receptor (MR) antagonist (MRA) with
high binding affinity, high MR selectivity and a short plasma half-life. In two major endpoint …

Diabetic kidney disease (DKD) is a common disorder with numerous severe clinical
implications. Due to a high level of fibrosis and inflammation that contributes to renal and …

Nonsteroidal mineralocorticoid receptor antagonists (MRAs) present a promising therapeutic
option in cardiorenal diseases, mitigating the limitations of steroidal MRAs. Finerenone, a …

Over the past decades, research has clearly established the important role of the
mineralocorticoid receptor (MR) in both renal and extra-renal tissues. Recently, caveolin-1 …

Background The mineralocorticoid receptor plays a significant role in the development of
chronic kidney disease (CKD) and associated cardiovascular complications. Classic …

Heart failure (HF) constitutes a major determinant of outcome in chronic kidney disease
(CKD) patients. The main pattern of HF in CKD patients is preserved ejection fraction …

Background: Mineralocorticoid receptor plays an important pathophysiological role in
cardiorenal diseases by causing inflammation and fibrosis. Mineralocorticoid receptor …